Foghorn launches with $50M for chromatin remodeling platform

Flagship Pioneering's Flagship VentureLabs launched chromatin remodeling company Foghorn Therapeutics Inc. (Cambridge, Mass.) with a $50 million capital commitment. Foghorn's Gene Traffic Control platform identifies small molecules capable of

Read the full 296 word article

User Sign In